Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
rotavirus type G1, rotavirus type G2, rotavirus type G3, rotavirus type G4, rotavirus type P1A
Merck Sharp & Dohme B.V. Waarderweg 39
J07BH02
rotavirus type G1, rotavirus type G2, rotavirus type G3, rotavirus type G4, rotavirus type P1A
not less than 2,2x10^6IU+ not less than 2,8x106IU+ not less than 2,2x10^6IU+ not less than 2x10^6IU+ not less than 2,3x10^6IU
solution oral
(1) plastic tube 2ml and (10) plastic tube 2ml
Prescription
Registered
2021-06-29
1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT RotaTeq Solution for oral administration RotaTeq is a live, oral pentavalent vaccine for use in the prevention of rotavirus gastroenteritis. The vaccine contains 5 live reassortant rotaviruses. The rotavirus parent strains of the reassortants were isolated from human and bovine hosts. Four reassortant rotaviruses express one of the outer capsid VP7 proteins (serotype G1, G2, G3, or G4) from the human rotavirus parent strains and the VP4 attachment protein (serotype P7[5]) from the bovine rotavirus parent strain. The fifth reassortant virus expresses the VP4 attachment protein (serotype P1A[8]) from the human rotavirus parent strain and the outer capsid VP7 protein (serotype G6) from the bovine rotavirus parent strain. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (2.0 mL) contains: _ACTIVE INGREDIENTS_ : human-bovine rotavirus reassortants (live), produced in Vero cells: G1, G2, G3, G4, and P1A[8]. The minimum dose levels of the reassortants are as follows: rotavirus type G1 not less than 2.2 x 10 6 infectious units rotavirus type G2 not less than 2.8 x 10 6 infectious units rotavirus type G3 not less than 2.2 x 10 6 infectious units rotavirus type G4 not less than 2.0 x 10 6 infectious units rotavirus type P1A[8] not less than 2.3 x 10 6 infectious units This vaccine contains 1 080 mg sucrose. 3. PHARMACEUTICAL FORM Solution for oral administration Pale yellow clear liquid that may have a pink tint 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS RotaTeq is indicated for the active immunisation of infants from the age of 6 weeks to 32 weeks for prevention of gastroenteritis due to rotavirus infection. RotaTeq is to be used on the basis of official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Posology. _ _From birth to 6 weeks _ RotaTeq is not indicated in this subset of pediatric population. The safety and efficacy of RotaTeq in individuals from birth to 6 weeks of age have not been established. _From 6 weeks to 32 wee Read the complete document